ClinicalTrials.gg

Program

nalmefene

Also written as “Nalmefene”, “Nalmefene hydrochloride” and “Nalmefene + 0.94% MgCl2”.

Its studies are mostly in Alcoholism · Opiate Overdose · Pruritus · Renal Insufficiency · Smoking Cessation, led by 7 companies.

Furthest: phase 4, since Jul 17, 201420 company-led studies, 1 open or runningNext primary completion: Mar 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeck60 open or runningphase 4since Jul 17, 2014Dec 18, 2008none ahead
Indivior Pharmaceuticals30 open or runningphase 1since Feb 15, 2021Feb 15, 2021none ahead
Knoa Pharma30 open or runningphase 4since Mar 15, 2023Mar 15, 2023none ahead
Otsuka30 open or runningphase 3since Feb 10, 2015Feb 10, 2015none ahead
Somaxon Pharmaceuticals20 open or runningphase 3since Aug 17, 2005Aug 17, 2005none ahead
Tharimmune21 open or runningphase 2since Dec 3, 2024Dec 27, 2023Mar 1, 2027phase 2 · NCT06733519
Serentis10 open or runningphase 2since Feb 5, 2009Feb 5, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Aug 17, 2005.

  1. Dec 18, 2008H. Lundbeck's first studies: 3 phase 3 studies in AlcoholismNew to H. LundbeckH. Lundbeck · NCT00811941, NCT00811720, NCT00812461
  2. Feb 5, 2009Serentis's first study: phase 2 study in PruritusNew to SerentisSerentis · NCT00838708 · 62 enrolled · United States
  3. Aug 22, 2013Phase 1 study in Renal InsufficiencyH. Lundbeck · NCT01934166 · 32 enrolled · Germany
  4. Jul 17, 20142 phase 4 studies in AlcoholismH. Lundbeck · NCT02195817, NCT02197598
  5. Feb 10, 2015Otsuka's first studies: 2 phase 3 studies in AlcoholismNew to OtsukaOtsuka · NCT02382276, NCT02364947
  6. Jan 25, 2016Phase 1 study in AlcoholismOtsuka · NCT02679469 · 7 enrolled · Japan
  7. Feb 15, 2021Indivior Pharmaceuticals's first study: phase 1 study in PharmacokineticsNew to Indivior PharmaceuticalsIndivior Pharmaceuticals · NCT04759768 · 68 enrolled · United States
  8. Mar 30, 2021Phase 1 study in PharmacodynamicIndivior Pharmaceuticals · NCT04828005 · 84 enrolled · United States
  9. Jan 21, 2022Phase 1 study in Opiate OverdoseIndivior Pharmaceuticals · NCT05219669 · 24 enrolled · United States
  10. Mar 15, 2023Knoa Pharma's first study: phase 4 study in Opiate OverdoseNew to Knoa PharmaKnoa Pharma · NCT05808881
  11. Dec 27, 2023Tharimmune's first study: phase 1 study in HealthyNew to TharimmuneTharimmune · NCT06198686 · 20 enrolled · United States
  12. Dec 2, 2024Phase 1 study in Opiate OverdoseKnoa Pharma · NCT06719986 · 24 enrolled · United States
  13. Dec 3, 2024Phase 2 study in PruritusTharimmune · NCT06733519 · 40 planned
  14. Apr 15, 2026Phase 1 study in Opiate OverdoseKnoa Pharma · NCT07543276 · 13 enrolled · United States

Ahead

  1. Mar 1, 2027Primary completion: phase 2 study in PruritusTharimmune · NCT06733519

TargetBeta

“Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
NalbuphineruleTrevi Therapeuticsphase 420
cebranopadolruleTris Pharmaphase 318

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07543276Opiate Overdose · United States1CompletedKnoa PharmaApr 3, 202613
NCT06733519Pruritus2Not yet recruitingTharimmuneMar 1, 202740
NCT06719986Opiate Overdose · United States1CompletedKnoa PharmaDec 23, 202224
NCT06198686Healthy · United States1CompletedTharimmuneFeb 11, 202420
NCT05808881Opiate Overdose4WithdrawnKnoa PharmaMay 20240
NCT05219669Opiate Overdose · United States1CompletedIndivior PharmaceuticalsNov 19, 202124
NCT04828005Pharmacodynamic · United States1CompletedIndivior PharmaceuticalsMar 14, 202284
NCT04759768Pharmacokinetics · United States1CompletedIndivior PharmaceuticalsMay 17, 202168
NCT02679469Alcoholism · Japan1CompletedOtsukaMar 20167
NCT02382276Alcoholism · Japan3CompletedOtsukaJan 18, 2017405
NCT02364947Alcoholism · Japan3CompletedOtsukaJul 30, 2016678
NCT02197598Alcoholism · Germany4CompletedH. LundbeckDec 201545
NCT02195817Alcoholism · France, Germany, Spain and more4TerminatedH. LundbeckFeb 2016378
NCT01934166Renal Insufficiency · Germany1CompletedH. LundbeckAug 201432
NCT00838708Pruritus · United States2CompletedSerentisJul 200962
NCT00812461Alcoholism · Belgium, Czech Republic, France and more3CompletedH. LundbeckMar 2011678
NCT00811941Alcoholism · Czech Republic, Estonia, Hungary and more3CompletedH. LundbeckNov 2010665
NCT00811720Alcoholism · Austria, Finland, Germany and more3CompletedH. LundbeckOct 2010598
NCT00202696Smoking Cessation · United States2CompletedSomaxon PharmaceuticalsMar 200676
NCT00132119Gambling3CompletedSomaxon PharmaceuticalsAug 2006233

How it is read

Names in the registry

  • “Nalmefene”, 5 entries
  • “Nalmefene hydrochloride”, 3 entries
  • “Nalmefene + 0.94% MgCl2”, 2 entries
  • “Nalmefene Hydrochloride”, 2 entries
  • “nalmefene”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.